Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals The Janssen Pharmaceutical Companies
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated.
U S Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Janssen Pharmaceuticals : Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
05/26/2021 | 08:49am EDT
Send by mail :
Message : +1 800-526-7736 Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals for the first FDA-approved treatment in a rare blood cell disorder RARITAN, N.J., May 26, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for
Share this article
Share this article
NEWARK, Calif., May 24, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor (IL-23R) antagonist peptide. This study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers. Recruitment for the study is ongoing. PN-232 is a second-generation, oral, IL-23 receptor antagonist candidate currently being developed in collaboration with Janssen Research & Development, LLC, said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. Today s announcement marks another step forward in our joint efforts to discover and develop novel oral treatment regimens for diseases that are moderated by intervention on the IL-23 pathway. Our joint efforts have now led to three different oral IL-23 antagonists: PTG-200, PN-235, and PN-232.